Archived Content

The content on this page is provided for reference purposes only. This content has not been altered or updated since it was archived.

Advisory Committees

Agenda

BLOOD PRODUCTS ADVISORY COMMITTEE
103rd Meeting, June 12, 2012

National Institutes of Health
Building 29, Conference room 29-121

Tuesday, June 12, 2012

12:00 p.m. 

Opening Remarks, Blaine Hollinger, M.D., Chair

Statement of Conflicts of Interest, Announcements

12:10 p.m.

Topic I:  Review of the Research Programs in the Laboratories of Emerging Pathogens and Bacterial and
Transmissible Spongiform Encephalopathy Agents, Division of Emerging and Transfusion Transmitted Diseases, OBRR

  1. Overview of CBER Research, Carolyn Wilson, Ph.D., CBER, FDA (15’)
  2. Overview of the Division of Emerging and Transfusion Transmitted Diseases Research Program, Hira Nakhasi, Ph.D., DETTD, OBRR, FDA (15’)
  3. Overview of the Laboratory of Emerging Pathogens (LEP), Sanjai Kumar, Ph.D., DETTD, OBRR, FDA (60’)

Questions & Answers (10’)

  1. Overview of the Laboratory of Bacterial and Transmissible Spongiform Encephalopathy Agents (LBTSEA), David  Asher, M.D., DETTD, OBRR, FDA (30’)

Questions and Answers (10')

2:30 p.m.Open Public Hearing
3:30 p.m.Break
3:45 p.m.Closed Committee Discussion
4:30 p.m.Adjournment

Page Last Updated: 10/13/2016
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English